Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L1BS
|
||||
| Former ID |
DIB007298
|
||||
| Drug Name |
PF-454583
|
||||
| Synonyms |
PF-454583; PF-4926965; Opioid receptor-like 1 (ORL1) antagonists (Alzheimer's disease), Pfizer
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] | Investigative | [1] | ||
| Company |
Pfizer Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H26ClFN4O2
|
||||
| Canonical SMILES |
CN(C)C(=O)C(CN1CCC2(CC1)C3=C(CO2)C=CC(=C3)F)CN4C=C(C=N4<br />)Cl
|
||||
| InChI |
1S/C21H26ClFN4O2/c1-25(2)20(28)16(12-27-13-17(22)10-24-27)11-26-7-5-21(6-8-26)19-9-18(23)4-3-15(19)14-29-21/h3-4,9-10,13,16H,5-8,11-12,14H2,1-2H3
|
||||
| InChIKey |
BVXVLXUGXQOMEP-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Nociceptin receptor | Target Info | Antagonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.